Stocks › ABBV

AbbVie ABBV

US equityMarket cap rank #24

$265.06

−$0.03 (-0.01%)

Market open · Sep 24, 2:00 pm ET

After hours $265.12 +0.02%

Open$265.31

Prev close$265.08

Day range$263.09 – $267.41

Volume1.64M

Market cap$468.38B

P/E (TTM)74.9

Dividend yield2.54%

BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $282 Market news · 8 Sep 2026
News On Apogee Therapeutics Inc. (APGE) Now Under ABBV Dow Jones · 4 Sep 2026
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $300 Market news · 4 Sep 2026
Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280 Market news · 4 Sep 2026
TD Cowen Initiates AbbVie(ABBV.US) With Buy Rating, Announces Target Price $280 Market news · 4 Sep 2026
RBC Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280 Market news · 15 Sep 2026
Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280 Market news · 11 Sep 2026
RBC Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280 Market news · 11 Sep 2026
Berenberg Bank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $275 Market news · 11 Sep 2026
HSBC Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $315 Market news · 10 Sep 2026
Erste Group Upgrades AbbVie(ABBV.US) to Buy Rating Market news · 5 Aug 2026
Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $288 Market news · 4 Aug 2026
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $303 Market news · 20 Aug 2026
AbbVie 2Q U.S. HUMIRA Rev $425M ABBV Dow Jones · 31 Jul 2026
4: AbbVie | 4: Statement of changes in beneficial ownership of securities-Director Davis Jennifer L. SEC · 13 May 2026